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Protein arginine methyltransferase 7 (PRMT7) is a member of a family of enzymes that catalyze the
transfer of methyl groups from S-adenosyl-L-methionine to nitrogen atoms on arginine residues.
Here, we describe the crystal structure of Caenorhabditis elegans PRMT7 in complex with its reaction
product S-adenosyl-L-homocysteine. The structural data indicated that PRMT7 harbors two tandem
repeated PRMT core domains that form a novel homodimer-like structure. S-adenosyl-L-homocyste-
ine bound to the N-terminal catalytic site only; the C-terminal catalytic site is occupied by a loop
that inhibits cofactor binding. Mutagenesis demonstrated that only the N-terminal catalytic site
of PRMT7 is responsible for cofactor binding.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ylation of Sm proteins, snRNP biogenesis [6], and the expression ofProtein arginine methylation is a common post-translational
modiﬁcation that has been implicated in numerous biological pro-
cesses. Protein arginine methyltransferases (PRMTs) catalyze the
transfer of methyl groups from S-adenosyl-L-methionine (AdoMet)
to nitrogen atoms on arginine residues to produce methylarginine
and S-adenosyl-L-homocysteine (AdoHcy). The mammalian PRMT
family consists of nine members that are classiﬁed into three types
(I, II, and III) according to their catalytic functions. Type I and II
PRMTs produce asymmetric dimethylarginine and symmetric
dimethylarginine, respectively, whereas type III PRMTs produce
monomethylated arginine (Fig. S1a). All PRMTs contain a con-
served core comprising a Rossmann fold domain and a b-barrel
domain, as well as additional domains that confer various func-
tions (Fig. S1b). PRMTs also contain a set of conserved sequence
motifs and double E and threonine–histidine–tryptophan (THW)
loops that are speciﬁc to the PRMT family (Fig. S2) [1].
It was reported recently that mouse and human PRMT7 exhibit
type III activity [2,3]. The physiological roles of mammalian PRMT7
are associated with broad cellular processes [4,5], including meth-genes involved in DNA repair [7]. Furthermore, PRMT7 appears to
play a role in the maintenance of the pluripotent state of undiffer-
entiated embryonic stem cells and germ cells [8], and a recent study
reported that it antagonizes mixed-lineage leukemia 4-mediated
cellular differentiation [9]. PRMT7 has also been associated with
the promotion of breast cancer metastasis [10]. These ﬁndings sug-
gest that PRMT7 is a potential target for anti-cancer therapeutics.
Structural studies have revealed that type I PRMTs contain a
single PRMT core domain and dimerization of these proteins is
required for their catalytic activity [11]. PRMT7 is unusual in that
it contains two PRMT core domains in tandem (Fig. 1a). The
sequence of the N-terminal domain of PRMT7 is well conserved
between other PRMT family members; however, conservation of
the C-terminal domain, including the residues within the con-
served motifs, is relatively poor, suggesting that this domain is
non-functional [12]. To obtain an insight into its structural organi-
zation, oligomerization, and function, we determined the crystal
structure of Caenorhabditis elegans PRMT7 (CePRMT7) in complex
with its substrate AdoHcy.
2. Materials and methods
2.1. Protein expression and puriﬁcation
For protein expression, Escherichia coli (BL21 (DE3) pLysS) were
transformed with the pGEX6P-1 plasmid encoding the full-length
Elution voume (mL)
A 2
80
(m
AU
)
a
PRMT1
PRMT7
Rossmann
fold
β
β β
-barrel
Core domain
N-Terminal core C-Terminal core
N- -barrelN-Rossmann
fold
C- -barrelC-Rossmann
fold
b
q(Å-1)
In
te
ns
ity
 (l
og
 s
ca
le
)
+AdoMet
Apo 
c
Fig. 1. Overview of PRMT1 and PRMT7, and the solution properties of CePRMT7. (a) Schematic representation of the domain structures of PRMT1 and PRMT7. The Rossmann
fold domain and the b-barrel domain are shown in red and green, respectively. PRMT1 contains a single core domain whereas PRMT7 contains two core domains in tandem.
(b) Gel ﬁltration chromatography proﬁle of CePRMT7. For comparison, the elution volumes of bovine serum albumin (66 kDa) and alcohol dehydrogenase (150 kDa) are
shown above the CePRMT7 elution proﬁle. (c) SAXS analysis of CePRMT7. The scattering curves of the apo and AdoMet-bound forms of CePRMT7 are shown in green and red,
respectively.
M. Hasegawa et al. / FEBS Letters 588 (2014) 1942–1948 1943GST-fused CePRMT7 gene [13]. The cells were grown in LB medium
until they reached a density of 0.4–0.5 at 660 nm. After the addi-
tion of 0.13 mM IPTG, the cells were incubated at 18 C overnight.
GST-fused CePRMT7 was puriﬁed using Glutathione Sepharose 4B
(GE Healthcare) and the GST-tag was removed using PreScission
Protease (GE Healthcare). Additional puriﬁcation of CePRMT7 was
performed using HiTrapQ (GE Healthcare) and Superdex200 (GE
Healthcare) columns. Puriﬁed CePRMT7 was concentrated to 15–
22 mg/ml.
2.2. Crystallization
The crystal for the tetragonal form of CePRMT7 was obtained by
incubating CePRMT7 with 0.6 mM histone H4 peptide and 1 mM
AdoHcy. Sitting drops were set up at 20 C by mixing the protein
solution with reservoir solution containing 50 mM Bis–Tris (pH
6.7–7.0) and 9.5–13% (w/v) PEG MME 5000. The trigonal form crys-
tal was obtained by sitting drop vapor diffusion at 15 C by mixing
CePRMT7 with 1.4 mM AdoHcy and the mother liquid containing
100 mM Tris (pH 8.5) and 2 M ammonium phosphate. Heavy atom
derivatives were prepared with a solution containing 44 mM
Bis–Tris (pH 6.9), 15% (w/v) PEG MME 5000, and 1.25 mM
KAu(CN)4. After soaking for 26 h, the derivatives were transferred
to the harvesting solution (50 mM Bis–Tris (pH 6.9) and 16% (w/
v) PEG MME 5000) and then to cryoprotectant solution (50 mM
Bis–Tris (pH 6.9), 22% (w/v) PEG MME 5000). The native crystals
were transferred to a harvesting solution (25 mM Bis–Tris (pH
6.7–7.0), 15% (w/v) PEG MME 5000) and the solution was changed
to cryoprotectant containing 1 mM AdoHcy by vapor-diffusion
overnight (reservoir solution: 50 mM Bis–Tris (pH 6.7–7.0), 30%
(w/v) PEG MME 5000). The data were collected on a BL-5A
beamline at The Photon Factory (PF; Tsukuba, Japan) and on aBL-44XU beamline at SPring-8 (Harima, Japan). The collected data
were processed using the HKL2000 package [14].
2.3. Structure determination
The structure of the tetragonal form of CePRMT7 was solved by
single-wavelength anomalous diffraction using the SHARP/auto-
SHARP program [15]. The trigonal structure was determined by
molecular replacement using the Phaser program [16] and the
structure of the tetragonal form of CePRMT7 as a search model. Ini-
tial model building was performed using the ARP/wARP program
[17]. Manual model building and structure reﬁnement was per-
formed using the Coot [18] and Refmac5 [19] packages, respec-
tively. We added the H4 peptide to determine the structure
complexed with the peptide, but the electron density correspond-
ing to the peptide was not observed. The geometry of the structure
was veriﬁed using the PROCHECK program [20]. After initial phase
determination, huge electron density was observed around Cys207,
Cys345, Cys347, and His350, which were positioned in close prox-
imity (Fig. S3a). During the reﬁnement process, a disulﬁde bond
between Cys207 and Cys345 and a covalent bond between the Sc
atom of Cys347 and the Nd1 atom of His350 were incorporated
into the model to minimize the residual density. Dual conformers
for Cys345 and Cys347 were also incorporated (Fig. S3b). The dis-
tance between the Sc atoms of Cys207 and Cys347 was 2.0 Å and
the distance between the Sc atoms of Cys345 and Cys347 was
1.8 Å; these distances were small enough to enable the formation
of disulﬁde bonds. Therefore, the electron density map was derived
from various combinations of covalent bonds between these resi-
dues. However, we were unable to generate a more precise model
due to the limited resolution. Uninterpretable electron density was
observed around SAH molecule. A summary of the crystallographic
1944 M. Hasegawa et al. / FEBS Letters 588 (2014) 1942–1948measurements and statistics is shown in Table S1. The coordinate
and structure factor data have been deposited to the Protein Data
Bank (PDB) under the PDB IDs 3WSS and 3WST.
2.4. Small-angle X-ray scattering (SAXS)
SAXS data were collected using beamline BL-10C at the High
Energy Accelerator Research Organization (KEK/PF). Phosphate-
buffered saline containing 1 mM DTT with or without 0.8 mM Ado-
Met was used as the measurement solution. The radius of gyration
was calculated using the Primus program [21]. Details of the exper-
imental conditions and results are summarized in Table S2.
2.5. AdoMet binding assay
GST-fused CePRMT and its mutant (G72A) were used for the
AdoMet binding assay. The binding assay and generation of the
mutant were performed as described previously [13].
3. Results
3.1. Monomer structure of CePRMT7
First, we examined the solution properties of CePRMT7 using gel
ﬁltration column chromatography and SAXS analyses. The gel ﬁltra-a b
c
Fig. 2. Structure of CePRMT7. (a) The monomeric structure of CePRMT7 in the tetragona
the N-terminal dimerization arm are shown in red, green, and yellow respectively. Th
dimerization arm are shown in magenta, dark green, and coral, respectively. The connec
AdoHcy in the N-terminal Rossmann fold domain is also indicated in stick model. (b) A to
to the structure in the tetragonal form. Helices and strands are denoted by cylinders and a
the interface are shown in Fig. S2. The residues in the N-terminal Rossmann fold dom
interface are shown in red, green, and yellow, respectively; the residues in the equivalen
residues in the connecting loop is shown in black.tion chromatography proﬁle indicated that CePRMT7 was eluted as
a monomer (Fig. 1b). Consistent with this result, the SAXS analysis
revealed that both apo-CePRMT7 and AdoMet-bound CePRMT7
exist as monomers in solution, demonstrating that the oligomeric
state of the enzyme is independent of cofactor binding (Fig. 1c).
Next, we determined the crystal structures of the tetragonal
(P43212) and trigonal (P31) forms of AdoHcy-bound CePRMT7.
Fig. 2a and b shows the monomeric structure and topology of the
protein, respectively. Analyses of the crystallization data indicated
that the tetragonal form of CePRMT7 contains one molecule in an
asymmetric unit, while the trigonal form contains eighteen mole-
cules forming three spherical cages, each comprising six monomers
in an asymmetric unit (Fig. S4a). Despite the differences in the crys-
tallographic environments, the overall determined structures of the
trigonal and tetragonal forms of CePRMT7 were almost identical
(root mean square deviation, 0.7 Å). Because the quality of data
for the tetragonal form of CePRMT7was higher than that for the tri-
gonal form, the tetragonal form was used for all further analyses,
although it is worth noting that the trigonal form contains addi-
tional b-sheets at the N-terminal region (bN-1, bN0) (Fig. S4b and c).
3.2. Formation of a homodimer-like structure
Dimerization of the PRMT core domain is required for the enzy-
matic activity of type I PRMTs [11]. The dimerization interfaces ofl form. The N-terminal Rossmann fold domain, the N-terminal b-barrel domain, and
e C-terminal Rossmann fold domain, C-terminal b-barrel domain, and C-terminal
ting loop between the N-terminal and C-terminal core domains is shown in black.
pological illustration of CePRMT7. The secondary structures were assigned according
rrows, respectively. (c) The dimerization interface of CePRMT7. The residues forming
ain, N-terminal b-barrel domain, and N-terminal dimerization arm that form the
t C-terminal domains are shown in magenta, dark green, and coral, respectively. The
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tion arm in the b-barrel domain. Dimeric PRMTs usually include
a cavity at the center of their core. Notably, although CePRMT7
exists as a monomer in solution, the structural analysis revealed
that it forms a homodimer-like structure comprising its N-terminal
and C-terminal core domains (Fig. 2a). Analysis of the crystal struc-
ture revealed that the N-terminal and C-terminal domains of
CePRMT7 are topologically similar (Fig. 2b) and are packed tightly
with buried surface areas of 2372 Å2 (Fig. 2c). The crystallization
data also indicated that the N-terminal and C-terminal Rossmann
folds of CePRMT7 (amino acids 21–171 and 349–481, respectively)
are structurally similar to the Rossmann fold of rat PRMT1 (amino
acids 38–175), with root mean square deviations of 1.5 Å and 2.5 Å,
respectively (Fig. 3a). Similarly, the N-terminal and C-terminal b-
barrel domains of CePRMT7, excluding the dimerization arm, are
topologically similar to that of rat PRMT1, with root mean square
deviations of 2.4 Å and 2.9 Å, respectively (Fig. 3b). The dimeriza-
tion arm of the N-terminal core domain of CePRMT7 is a loop-rich
structure with one short a-helix, while the C-terminal core domain
has a helical dimerization arm containing two short b-strands
(Fig. 3b). The orientations of the N-terminal and C-terminal dimer-
ization arms of CePRMT7 are different (Fig. S5); as a result, the cav-
ity in the homodimer is almost completely closed by the Nb7–Nb70,
Nb11–Nb12, Cb7–Cb70, and Cb11–Cb12 regions, creating a new
dimerization interface (Figs. 2c and S2).
3.3. Structure of the active site of CePRMT7 and its ability to bind
AdoMet
A clear electron density corresponding to the AdoHcy cofactor
was observed in the N-terminal Rossmann fold of the CePRMT7
crystal structure (Fig. 4a). CePRMT7 recognized AdoHcy in a man-
ner similar to that of other PRMTs, indicating that PRMT family
members share similar mechanisms of cofactor binding and catal-
ysis. By contrast, no electron density was observed in the cofactor
binding pocket of the C-terminal Rossmann fold. Unlike the N-ter-a
b
Fig. 3. Comparison of the Rossmann fold and b-barrel domains in CePRMT7 and rat PRM
terminal Rossmann fold domain of CePRMT7, and the Rossmann fold domain of rat PRMT
as a stick model. (b) The structures of the N-terminal b-barrel domain of CePRMT7, the
shown in green, dark green, and light green, respectively. The N-terminal dimerization a
arm of rat PRMT1 are shown in yellow, coral, and light yellow, respectively.minal binding pocket, the C-terminal binding pocket was occupied
by the double E loop and motif I of the C-terminal Rossmann fold
domain, where the loops were stabilized by multiple hydrogen
bonds, thereby inhibiting cofactor binding (Figs. 4b and c, and
S2). Because of its differential structural features and the fact that
the C-terminal active site lacks the catalytic glutamate residue in
the double E loop that is conserved in all PRMT family members
(Fig. S2), we hypothesized that the C-terminal domain of CePRMT7
is non-functional. To conﬁrm this hypothesis, we performed a com-
petitive assay using 3H-labeled and non-isotopically labeled Ado-
Met. CePRMT7 was able to bind to 3H-AdoMet binding ability
and this binding was competitively abrogated by the addition of
an excess of non-isotopically labeled AdoMet. Mutation of
CePRMT7 at Gly72 (G72A) in motif I reduced its AdoMet binding
ability markedly (Fig. 4d). These results demonstrate that the N-
terminal PRMT core of CePRMT7 is responsible for its cofactor
binding ability.
3.4. Arginine binding pocket
In general, the THW loop, double E loop and aY helix of PRMTs
form an arginine binding pocket adjacent to the cofactor binding
site (Fig. 5a) [22]. Analysis of the crystal structure of CePRMT7
revealed that, in this protein, the THW loop is positioned in close
proximity to the double E loop, enabling the formation of a hydro-
gen bond between Thr144 in the double E loop and the main chain
atom of Met302 in the THW loop. Moreover, the THW loop is posi-
tioned in close proximity to the aY helix due to an interaction
between Asp35 in the aY helix and Asp299 in the THW loop, which
liberates the end of the aY helix. These conformational changes
cause Phe33 in the aY helix to be located close to Glu149
(Fig. 5b and c); as a result, the entrance to the arginine binding
pocket of CePRMT7 is much narrower than those of rat PRMT1
and human PRMT5 (Fig. 5c). The THW loop in CePRMT7 is ﬁxed
by a network of direct and water-mediated hydrogen bonds
that include Asp299 (corresponding to ‘‘Thr’’ in the THW loop),T1. (a) The structures of the N-terminal Rossmann fold domain of CePRMT7, the C-
1 (PDB id: 1ORI) are shown in red, magenta, and pink, respectively. AdoHcy is shown
C-terminal b-barrel domain of CePRMT7, and the b-barrel domain of rat PRMT1 are
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Fig. 4. Structure and activity of the cofactor binding site of CePRMT7. (a) A model of the AdoHcy binding site in CePRMT7. The residues that interact with AdoHcy and the
catalytic glutamate residues in the double E loop are shown as stick models. The mFo-DFc electron density map around AdoHcy was contoured at 3r. Carbon atoms of
AdoHcy and those of catalytic site residues are colored in gold and red, respectively. Oxygen, nitrogen, and sulfur atoms are colored in tan, blue, and yellow respectively.
Water molecules are shown as red balls and hydrogen bonds are shown as dashed lines. (b) The putative catalytic site in the C-terminal Rossmann fold domain of CePRMT7.
The residues in motif I and the double E loop that form hydrogen bonds are shown as stick models. Carbon, oxygen, nitrogen and sulfur atoms are colored in magenta, tan,
blue and yellow, respectively. Water molecules are shown as red balls and hydrogen bonds are shown as dashed lines. (c) A comparison of the motif I and double E loop
regions in the N-terminal and C-terminal Rossmann fold domains of CePRMT7. AdoHcy is shown as a stick model. Loops of the N-terminal and C-terminal core domain are
shown in red and magenta, respectively. (d) An AdoMet binding assay of recombinant wild-type CePRMT7 and its G72A mutant (upper panel). The recombinant proteins were
mixed with 3.6 nM 3H-labeled AdoMet in the presence or absence of 1 lM unlabeled AdoMet as a competitor, and then cross-linked by UV irradiation. Protein-bound 3H-
labeled AdoMet was analyzed by SDS–PAGE followed by autoradiography. Coomassie Brilliant Blue (CBB) staining of the same gel was used as a loading control.
1946 M. Hasegawa et al. / FEBS Letters 588 (2014) 1942–1948Tyr537, and Gln532 (Fig. 5b). Notably, these residues are conserved
among PRMT7 proteins from various species (Fig. S2) and are
involved in the formation of the newly created dimerization
interface.4. Discussion
To our knowledge, this study is the ﬁrst description of the
crystal structure of PRMT7, which harbors unique core domains
in tandem. Analysis of the crystal structure indicated that, unlike
type I PRMTs, which require dimerization for enzymatic func-
tionality [11], a single PRMT7 molecule can form a homodi-
mer-like arrangement. The structural analysis indicated that
the cavity of PRMT7 is occupied, suggesting the restriction of
substrate access. However, although substrates access the bind-
ing site of PRMT1 through its cavity [11], it is possible that sub-
strate access PRMT7 from the top surface due to the closure of
the corresponding cavity. Acidic residues are concentrated at
the N-terminal Rossmann fold on the top surface of PRMT7; this
acidic environment might be important for substrate binding
(Fig. S6).
The huge and unclear electron density of CePRMT7 was derived
from complicated covalent bonds formed by Cys207, Cys345,Cys347, and His350. These covalent bonds likely contribute to sta-
bilization of the intra-domain interactions, but their exact function
remains unknown.
CePRMT5 has four conserved residues in its active site that are
likely to be important for type II activity: Phe379, Lys385,
Ser503, and Ser669 (corresponding to Phe327, Lys333, Ser439,
and Ser578 in human PRMT5) [23,24]. The corresponding residues
in type I PRMTs are Met, Arg, Tyr, and His, respectively. Notably,
PRMT7 contains type I PRMT-like residues (Met36, Arg42,
Thr144, and His300), all of which are conserved among PRMT7s
(Fig. S2). It should also be noted that these residues are located
at structurally similar positions. In PRMT1, the bulky Tyr148 resi-
due seems to push out the THW and double E loops, making the
entrance to the binding site wider. Conversely, a similar structural
change in PRMT7 would not occur due to the small side chain of
Thr144 (Fig. 5a and b). The Phe33 residue in CePRMT7, which
makes the entrance to the arginine pocket narrower, is converted
to Tyr in PRMT7 proteins from other species (Fig. S2). These bulky
Tyr residues would likely play a similar role to Phe33 in CePRMT7,
suggesting that the relatively narrow entrance to the arginine
binding pocket is a common structural feature of PRMT7 proteins.
Monomethylated arginine is unlikely to enter the binding pocket
due to the steric hindrance. Processive PRMT could facilitate dime-
thylation by forming a homodimer [11,25], because the product of
c
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M. Hasegawa et al. / FEBS Letters 588 (2014) 1942–1948 1947the ﬁrst methylation reaction can enter the active site of the sec-
ond molecule of the dimer without releasing the substrate from
PRMT. Assuming that PRMT7 catalyzes the reaction in a manner
similar to processive PRMT, the unique non-functional C-terminal
domain and the narrow arginine binding pocket entrance of PRMT7
may explain its function as a type III enzyme (Fig. S7).
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